Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLCs registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

WuXi PharmaTech Set To Compete Globally Following OECD Certification Of New Drug Toxicology Lab In China

This article was originally published in PharmAsia News

Executive Summary

BEIJING - Armed with a new certification on good laboratory practice compliance from the Organization for Economic Cooperation and Development, WuXi PharmaTech's preclinical testing facility could be poised to battle the globe's giants in providing toxicology services for international players

You may also be interested in...



Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma

BEIJING - Betting on the belief that Big Pharma will speed up the transfer of research and manufacturing to China, leading contract research organization WuXi PharmaTech is expanding its chemistry services even while preparing to launch a new biologics testing and production center near its headquarters in Shanghai

Fresh Off BMS Deal, Leading Chinese CRO WuXi PharmaTech Outlines Plan To Expand Biologics Business To Keep Pace With Big Pharma

BEIJING - Betting on the belief that Big Pharma will speed up the transfer of research and manufacturing to China, leading contract research organization WuXi PharmaTech is expanding its chemistry services even while preparing to launch a new biologics testing and production center near its headquarters in Shanghai

Despite Inflationary Headwinds, Chinese CRO WuXi PharmaTech Set To Ride Wave Of Global Outsourcing

BEIJING - Leading Chinese contract research organization WuXi PharmaTech will face inflationary pressure on profits this year, but stepped-up outsourcing of research to China by international pharmaceutical players and the Shanghai-based firm's expanding range of services are likely to ensure strong earnings through 2011 and beyond, according to a prominent analyst who monitors the country's healthcare sector

Related Content

UsernamePublicRestriction

Register

SC076036

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel